February 27, 2007
WEST SACRAMENTO, Calif., Feb. 27, 2007 - Lipomics Technologies, Inc., a privately
held company that specializes in the analysis of lipid metabolites, announced today that it
has entered into an agreement with The University of California, Davis to collaborate on
research projects with an emphasis on personalized medicine.
Lipomics will retain certain rights to develop diagnostic applications based on the data
from the studies. Lipomics seeks to partner with academic institutions and drug
companies to advance its goal of developing diagnostic tests for metabolic diseases.
“This is a valuable collaboration as we pursue discovery of markers for health and
disease. Understanding individual response is essential to understanding metabolic
disease and approaches to therapy and preventative care. We look forward to working
with one of the nation’s premier research institutions,” said Steve Watkins, president and
chief scientific officer at Lipomics.